Patents by Inventor M. Amin Khan

M. Amin Khan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20150376195
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: January 29, 2014
    Publication date: December 31, 2015
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20150368253
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: January 29, 2014
    Publication date: December 24, 2015
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20150368254
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: January 29, 2014
    Publication date: December 24, 2015
    Inventors: John A. Lowe, III, M. Amin Khan
  • SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20150368252
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: January 29, 2014
    Publication date: December 24, 2015
    Applicant: NAUREX, INC.
    Inventors: John A. Lowe, III, M. Amin Khan
  • NMDA Receptor Modulators and Uses Thereof
    Publication number: 20150336969
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: December 23, 2014
    Publication date: November 26, 2015
    Inventors: M. Amin Khan, Joseph R. Moskal, Paul Wood
  • NMDA Receptor Modulators and Uses Thereof
    Publication number: 20150315237
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: January 23, 2014
    Publication date: November 5, 2015
    Inventors: Joseph R. Moskal, M. Amin Khan
  • Methods for the synthesis of plasmalogens and plasmalogen derivatives, and therapeutic uses thereof
    Patent number: 9169280
    Abstract: A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves production of novel cyclic plasmalogen precursors of Formula A and their conversion to plasmalogens and plasmalogen derivatives of Formula B. Also disclosed is the therapeutic use of plasmalogens and derivatives thereof as produced by the synthetic route of the present invention.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: October 27, 2015
    Assignee: PHENOMENOME DISCOVERIES INC.
    Inventors: M. Amin Khan, Paul L. Wood, Dayan Goodenowe
  • Secondary structure stabilized NMDA receptor modulators and uses thereof
    Patent number: 9101612
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: August 11, 2015
    Assignee: Northwestern University
    Inventors: Joseph Moskal, M. Amin Khan
  • Methods for the synthesis of 13C labeled iodotridecane and use as a reference standard
    Patent number: 9012704
    Abstract: A method for preparing 13C labeled iodotridecane represented by Formula A: The method comprises the conversion of 13C labeled propargyl alcohol to 13C labeled iodotridecane via alkylation of propargyl alcohol with iododecane.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: April 21, 2015
    Assignee: Phenomenome Discoveries Inc.
    Inventors: M. Amin Khan, Paul L. Wood, Dayan Goodenowe
  • NMDA Receptor Modulators and Uses Thereof
    Publication number: 20150105364
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: October 10, 2013
    Publication date: April 16, 2015
    Applicant: Northwestern University
    Inventors: M. Amin Khan, Joseph Moskal, Paul Wood
  • Methods for the synthesis of 13C labeled plasmalogen
    Patent number: 9006472
    Abstract: A method for preparing 13C labeled plasmalogens as represented by Formula B: The method involves producing a 13C labeled cyclic plasmalogen precursor of Formula A: and conversion of the precursor to a plasmalogen of Formula B.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: April 14, 2015
    Assignee: Phenomenome Discoveries Inc.
    Inventors: M. Amin Khan, Paul L. Wood, Dayan Goodenowe
  • NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20150051262
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: October 24, 2012
    Publication date: February 19, 2015
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: M. Amin Khan, Joseph Moskal
  • METHODS FOR THE SYNTHESIS OF 13C LABELED DHA AND USE AS A REFERENCE STANDARD
    Publication number: 20140336397
    Abstract: A method for preparing 13C labeled docosahexaenoic acid (DHA) represented by Formula A: The method comprises the conversion of 2-pentyn-1-ol to 13C labeled DHA by reaction with propargyl alcohol, 13C labeled propargyl alcohol and methyl pent-4-ynoate. The various steps involved include tosylation, coupling, bromination, selective hydrogenation and ester hydrolysis to obtain the final product.
    Type: Application
    Filed: November 16, 2012
    Publication date: November 13, 2014
    Inventors: M. Amin Khan, Paul L. Wood, Dayan Goodenowe
  • METHODS FOR THE SYNTHESIS OF 13C LABELED PLASMALOGEN
    Publication number: 20140323749
    Abstract: A method for preparing 13C labeled plasmalogens as represented by Formula B: —The method involves producing a 13C labeled cyclic plasmalogen precursor of Formula A, and conversion of the precursor to a plasmalogen of Formula B. These plasmalogens may potentially be useful in the determination of both the mechanism of action as well as the fate of plasmalogens in the body.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 30, 2014
    Inventors: M. Amin Khan, Paul L. Wood, Dayan Goodenowe
  • METHODS FOR THE SYNTHESIS OF 13C LABELED IODOTRIDECANE AND USE AS A REFERENCE STANDARD
    Publication number: 20140309464
    Abstract: A method for preparing 13C labeled iodotridecane represented by Formula A. The method comprises the conversion of 13C labeled propargyl alcohol to 13C labeled iodotridecane via alkylation of propargyl alcohol with iododecane.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 16, 2014
    Inventors: M. Amin Khan, Paul L. Wood, Dayan Goodenowe
  • METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREOF
    Publication number: 20140296187
    Abstract: A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves production of novel cyclic plasmalogen precursors of Formula A and their conversion to plasmalogens and plasmalogen derivatives of Formula B. Also disclosed is the therapeutic use of plasmalogens and derivatives thereof as produced by the synthetic route of the present invention.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 2, 2014
    Inventors: M. Amin Khan, Paul L. Wood, Dayan Goodenowe
  • NMDA receptors modulators and uses thereof
    Patent number: 8673843
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: March 18, 2014
    Assignee: Northwestern University
    Inventors: Joseph Moskal, M. Amin Khan
  • Secondary Structure Stabilized NMDA Receptor Modulators and Uses Thereof
    Publication number: 20130053325
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.
    Type: Application
    Filed: February 11, 2011
    Publication date: February 28, 2013
    Inventors: Joseph Moskal, M. Amin Khan
  • NMDA Receptors Modulators and Uses Thereof
    Publication number: 20130035292
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Application
    Filed: June 18, 2012
    Publication date: February 7, 2013
    Inventors: Joseph Moskal, M. Amin Khan
  • HYDROXY FATTY ACID COMPOUNDS AND USES THEREOF FOR DISEASE TREATMENT AND DIAGNOSIS
    Publication number: 20120136057
    Abstract: A compound of formula (I): wherein R represents a hydroxy substituted C24-C40 straight chain aliphatic group containing at least one double bond in the carbon chain; and at least one carbon in the chain is substituted with a hydroxy group. Such compounds are useful for detecting inflammation, inflammatory disorders and cancer in a subject, and can also be used in therapeutic applications including treatment and/or prevention of these conditions. Pharmaceutical compositions, combinations and supplements, as well as methods of treatment using the described compounds are therefore also described.
    Type: Application
    Filed: July 29, 2010
    Publication date: May 31, 2012
    Applicant: PHENOMENOME DISCOVERIES INC.
    Inventors: Shawn Ritchie, Dayan Goodenowe, M. Amin Khan, Pearson W.K. Ahiahonu